{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:33:44Z","timestamp":1794285224818,"version":"4.9.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.04.082","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T13:42:14Z","timestamp":1525527734000},"page":"3468-3476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Heterologous prime\u2013boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus"],"prefix":"10.1016","volume":"36","author":[{"given":"Seo-Yeon","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Lim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TaeWoo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Lim","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Myeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hwan","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2018.04.082_b0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.082_b0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ajpath.2015.09.014","article-title":"Dipeptidyl peptidase 4 distribution in the human respiratory tract","volume":"186","author":"Meyerholz","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.vaccine.2018.04.082_b0015","unstructured":"World Health Organization. Middle East respiratory syndrome coronavirus [MERS-CoV]; 2016. <http:\/\/www.who.int\/emergencies\/mers-cov\/en\/> [accessed 20 August 2017]."},{"key":"10.1016\/j.vaccine.2018.04.082_b0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses\u2014drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.vaccine.2018.04.082_b0025","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2013.92","article-title":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4","volume":"23","author":"Wang","year":"2013","journal-title":"Cell Res"},{"key":"10.1016\/j.vaccine.2018.04.082_b0030","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.vaccine.2014.04.016","article-title":"Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice","volume":"32","author":"Coleman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.082_b0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.07.015","article-title":"MERS-CoV spike protein: targets for vaccines and therapeutics","volume":"133","author":"Wang","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.04.082_b0040","doi-asserted-by":"crossref","first-page":"11950","DOI":"10.1128\/JVI.01672-13","article-title":"Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies","volume":"87","author":"Song","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.04.082_b0045","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1016\/j.vaccine.2014.08.058","article-title":"Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB\/c mice","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.082_b0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/imm.12462","article-title":"Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus","volume":"145","author":"Guo","year":"2015","journal-title":"Immunology"},{"issue":"16","key":"10.1016\/j.vaccine.2018.04.082_b0055","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1128\/JVI.00614-15","article-title":"Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein","volume":"89","author":"Volz","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.04.082_b0060","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.082_b0065","doi-asserted-by":"crossref","first-page":"e81587","DOI":"10.1371\/journal.pone.0081587","article-title":"A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines","volume":"8","author":"Du","year":"2013","journal-title":"PLos ONE"},{"key":"10.1016\/j.vaccine.2018.04.082_b0070","doi-asserted-by":"crossref","unstructured":"Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 2014; 32(18):2100\u20138. doi:http:\/\/doi.org\/10.1016\/j.vaccine.2014.02.004","DOI":"10.1016\/j.vaccine.2014.02.004"},{"key":"10.1016\/j.vaccine.2018.04.082_b0075","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/21645515.2015.1021527","article-title":"Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus","volume":"11","author":"Tang","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.04.082_b0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virusres.2014.11.013","article-title":"Receptor-binding domain-based subunit vaccines against MERS-CoV","volume":"202","author":"Zhang","year":"2015","journal-title":"Virus Res"},{"issue":"12","key":"10.1016\/j.vaccine.2018.04.082_b0085","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2017.02.012","article-title":"MERS-CoV spike nanoparticles protect mice from MERS-CoV infection","volume":"35","author":"Coleman","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.082_b0090","doi-asserted-by":"crossref","unstructured":"Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 2015; 7(301):301ra132. doi:http:\/\/doi.org\/10.1126\/scitranslmed.aac7462","DOI":"10.1126\/scitranslmed.aac7462"},{"key":"10.1016\/j.vaccine.2018.04.082_b0095","doi-asserted-by":"crossref","first-page":"7712","DOI":"10.1038\/ncomms8712","article-title":"Evaluation of candidate vaccine approaches for MERS-CoV","volume":"6","author":"Wang","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2018.04.082_b0100","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2741\/2191","article-title":"Peptide vaccines against cancer, infectious diseases, and conception","volume":"12","author":"Naz","year":"2006","journal-title":"Front Biosci"},{"key":"10.1016\/j.vaccine.2018.04.082_b0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4167\/jbv.2013.43.1.18","article-title":"Ethical guidelines for use of experimental animals in biomedical research","volume":"43","author":"Cho","year":"2013","journal-title":"J Bacteriol Virol"},{"issue":"13","key":"10.1016\/j.vaccine.2018.04.082_b0110","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1073\/pnas.1323279111","article-title":"Rapid generation of a mouse model for Middle East respiratory syndrome","volume":"111","author":"Zhao","year":"2014","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.vaccine.2018.04.082_b0115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF02786470","article-title":"The paradigm of Thl and Th2 cytokines","volume":"20","author":"Singh","year":"1999","journal-title":"Immunol Res"},{"issue":"5388","key":"10.1016\/j.vaccine.2018.04.082_b0120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.282.5388.476","article-title":"Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine","volume":"282","author":"Wang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2018.04.082_b0125","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines","volume":"110","author":"Tatsis","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.vaccine.2018.04.082_b0130","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.4049\/jimmunol.1000338","article-title":"CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement for TLR and nucleotide-binding oligomerization domain-like receptor signaling","volume":"185","author":"Lindsay","year":"2010","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.04.082_b0135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/156652311796150372","article-title":"Adenoviral vector immunity: its implications and circumvention strategies","volume":"11","author":"Ahi","year":"2011","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.vaccine.2018.04.082_b0140","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2018.04.082_b0145","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"Barouch","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.082_b0150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.55.091902.104344","article-title":"Recent advances in the development of HIV-1 vaccines using replication incompetent adenovirus vectors","volume":"55","author":"Shiver","year":"2004","journal-title":"Annu Rev Med"},{"issue":"7090","key":"10.1016\/j.vaccine.2018.04.082_b0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.04.082_b0160","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.gt.3300665","article-title":"Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro","volume":"5","author":"Chill\u00f3n","year":"1998","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2018.04.082_b0165","first-page":"740","article-title":"Poly [lactic-glycolic] acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo","volume":"5","author":"Beer","year":"1998","journal-title":"Gene Ter"},{"issue":"20","key":"10.1016\/j.vaccine.2018.04.082_b0170","doi-asserted-by":"crossref","first-page":"10780","DOI":"10.1128\/JVI.77.20.10780-10789.2003","article-title":"Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier","volume":"77","author":"Xiang","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.04.082_b0175","doi-asserted-by":"crossref","unstructured":"Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3(10):e3548. doi:http:\/\/doi.org\/10.1371\/journal.pone.0003548","DOI":"10.1371\/journal.pone.0003548"},{"key":"10.1016\/j.vaccine.2018.04.082_b0180","doi-asserted-by":"crossref","unstructured":"Zhao J, Alshukairi AN, Baharoon SA, Ahmed WA, Bokhari AA, Nehdi AM, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses. Science 2017; 2(14):eaan5393. doi:http:\/\/doi.org\/10.1126\/sciimmunol.aan5393","DOI":"10.1126\/sciimmunol.aan5393"},{"issue":"10","key":"10.1016\/j.vaccine.2018.04.082_b0185","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.4049\/jimmunol.0900317","article-title":"Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens","volume":"182","author":"Tatsis","year":"2009","journal-title":"J Immunol"},{"issue":"17","key":"10.1016\/j.vaccine.2018.04.082_b0190","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1089\/10430349950016555","article-title":"Cellular immune responses of healthy individuals to intradermal administration of an E1\u2013E3- adenovirus gene transfer vector","volume":"10","author":"Harvey","year":"1999","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/j.vaccine.2018.04.082_b0195","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1128\/JVI.79.10.6516-6522.2005","article-title":"Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates","volume":"79","author":"Santra","year":"2005","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.04.082_b0200","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1164\/rccm.200209-982OC","article-title":"Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury","volume":"1689","author":"Hoshino","year":"2003","journal-title":"Am J Respir Crit Care med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.04.082_b0205","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.04.082_b0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.virol.2016.04.014","article-title":"Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease","volume":"494","author":"Hwang","year":"2016","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2018.04.082_b0215","doi-asserted-by":"crossref","first-page":"e1004757","DOI":"10.1371\/journal.ppat.1004757","article-title":"RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets","volume":"11","author":"Knudson","year":"2015","journal-title":"PLoS Pathog"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830598X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830598X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T06:23:39Z","timestamp":1561530219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1830598X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":43,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X1830598X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.082","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterologous prime\u2013boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}